Check Cap Ltd Stock
€2.36
Your prediction
Check Cap Ltd Stock
Pros and Cons of Check Cap Ltd in the next few years
Pros
Cons
Performance of Check Cap Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Check Cap Ltd | 13.460% | 24.551% | 1.961% | 62.703% | 6.667% | 33.333% | - |
Beximco Pharmaceuticals Ltd. GDR | - | -7.234% | 0.000% | 4.808% | -0.909% | -57.255% | -14.510% |
Cellectar BioSciences Inc. | 10.780% | 4.494% | 2.198% | 181.818% | 63.158% | -73.803% | - |
SELLAS Life Sciences Group Inc | -1.570% | -1.271% | -1.062% | -15.847% | -4.410% | -86.936% | -99.746% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.From an initial glance at the financial statements of Check Cap, a pharmaceutical company with the US symbol, it appears that the company has been experiencing some financial challenges. Over the years, the company's balance sheets and income statements reveal issues that may be concerning for investors. In order to provide a better understanding of Check Cap's financial performance, let us dive into a detailed analysis.
Pros
Decreasing Total Liabilities: Over the years, it is evident that Check Cap has successfully reduced its total liabilities. The total liabilities decreased from $4,968,000 in 2021 to $4,129,000 in 2022, potentially showing the company's ability to effectively manage its debt obligations.